Although the above-mentioned results may indicate the renal benefits of SGLT2 inhibitors in type 1 diabetes in certain circumstances, this comes with the reduction in insulin dose, which may make patients prone to DKA. Here, SLC5A2 is linked to type 1 diabetes mellitus.